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The authors reply: Although cardiogenic shock 
is rare in patients with pheochromocytoma, we 
agree with Whitelaw et al. that it is important for 
clinicians to be aware of this possibility, which 
was recently highlighted in a Case Record of the 
Massachusetts General Hospital.1 The cardiomy-
opathy, whether dilated or hypertrophic, may be 
completely reversible with tumor resection.2
Tassone comments on the role for measure-
ment of serum chromogranin A levels as a case 
detection test for pheochromocytoma. Chromo-
granin A is stored and released from dense-core 
secretory granules of neuroendocrine cells, and 
levels are elevated in most patients with pheo-
chromocytoma. However, a high chromogranin A 
level is not specific for pheochromocytoma, 
and elevations may be seen in patients with 
other neuroendocrine tumors or with non-neuro-
endocrine tumors, atrophic gastritis, or perni-
cious anemia. Elevations may also be seen in 
patients treated with proton-pump inhibitors 
and those with impaired hepatic or renal func-
tion. Thus, the estimated specificity of a high 
level of chromogranin A for pheochromocytoma 
is 50%.3 For these reasons, we do not recom-
mend measurement of chromogranin A levels as 
a case detection test for pheochromocytoma.
With regard to Tassone’s comment on the 
clonidine suppression test: it was developed in 
the early 1980s to address the high false-positive 
rate for plasma fractionated catecholamines.4 
Clonidine is a centrally acting α2-adrenergic 
receptor agonist that suppresses the release of 
catecholamines from neurons but does not af-
fect the secretion of catecholamines by a pheo-
chromocytoma. However, given the advances in 
laboratory methodology and measurement of frac-
tionated metanephrines in the urine and blood 
with use of appropriate reference ranges, the 
clonidine suppression test rarely has a role in the 
diagnosis of this disease.
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The “All of Us” Research Program
To the Editor: Denny and colleagues (Aug. 15 
issue)1 describe the progress of the All of Us Re-
search Program. In Scotland, which has a popu-
lation of 5.43 million, a patient registry 2 is 
achieving some of the advantages envisaged by 
All of Us. The Scottish Health Research Register 
(SHARE) began accessing data from electronic 
health records (EHRs) in 2011 and obtaining ge-
nomic data (from “leftover” blood samples) in 
2013; it now includes data on 270,604 persons 
who are 11 years of age or older (as of August 
2019) and has collected 97,642 blood samples. 
The means of recruitment include the SHARE 
website,3 awareness raising through printed ma-
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terials, social media, and radio, and face-to-face 
contact between paid recruiters and patients in 
hospitals and clinics. Persons attending health-
related events such as the opening of new facili-
ties, conferences, science fairs, open houses, and 
sports events are also recruited.
Participants agree to be contacted by SHARE 
to discuss participation in studies for which they 
meet inclusion criteria as described on the 
SHARE website. Researchers are then provided 
with contact details for potential study partici-
pants. So far, SHARE has supported 102 studies, 
including surveys, genetic linkage studies, and 
trials.
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To the Editor: The Special Report on the All of 
Us Research Program outlines many commend-
able features, including broad representation of 
populations and engagement of participants in 
planning. Nonetheless, only a single sentence ad-
dresses the failure to include children; it states 
that “protocols are being developed to enable en-
rollment.”
The failure to include children is a profound 
scientific flaw, in part because physical and be-
havioral exposures that occur during childhood 
(and in utero) determine future health. Other 
programs in the United States have protocols to 
enroll children and have enrolled thousands of 
pregnant women and children in population-
based research. This experience could have pro-
vided an important framework for All of Us, 
which could have included children so that risks 
in childhood would be incorporated from the 
inception of the program. Instead, these critical 
early life events are still not being addressed 
despite the billions of dollars invested. Women 
and children have long been overlooked in na-
tional studies, and the slow pace of bringing 
them into All of Us means that the most vulner-
able members of society are still not counted as 
“all of us.”
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The author and colleagues reply: We applaud 
the efforts of the SHARE program described by 
Sullivan et al. The use of clinical data and bio-
specimens obtained during clinical visits has 
proved to be a powerful model in other studies 
such as those in the Electronic Medical Records 
and Genomics (eMERGE) Network1 and the Mil-
lion Veteran Program.2 SHARE also allows re-
searchers to recontact participants; this is not usu-
ally a feature of biobanks, and it is an important 
part of All of Us. Collaboration and shared data 
standards among diverse international cohorts, 
as envisioned by the International HundredK+ 
Cohorts Consortium,3 will be important in the 
advancement of discovery and health care.
We thank Murray for highlighting the impor-
tance of the inclusion of children and pregnant 
women in All of Us. Indeed, these are under-
represented populations in biomedical research 
and will be an important part of our program as 
we aim to study health and disease across the 
human life span. A total of 3800 pregnant 
women have enrolled in All of Us, and 6021 
participants have shared their pediatric EHR 
information. All of Us will soon engage in a 
pilot to offer pregnant women who enroll in the 
program to also enroll in the PregSource project 
of the National Institutes of Health,4 a crowd-
sourced research project to collect data on ma-
ternal, fetal, and infant health. This is a first 
step in our effort to include data on pregnancy 
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notices
in the data set. The inclusion of children is cru-
cial to the success of All of Us. We have begun 
to work on the appropriate policies, protocols, 
communication methods, and infrastructure 
necessary to achieve this goal. Because overall 
recruitment in the All of Us program is still in 
the early stages, there is ample opportunity to 
expand to all populations, including children.
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HARVARD MEDICAL SCHOOL
The following courses will be offered in Boston: “Update in 
Internal Medicine 2019” (Dec. 8–14); “Nephrology 2020” 
(March 15–20); and “Musculoskeletal Ultrasound Hands-on 
Diagnostics and Guided Interventional Skills with Cadaver 
Lab” (March 28 and 29). They are jointly presented by Harvard 
Medical School and Beth Israel Deaconess Medical Center.
Contact the Department of Continuing Education, Harvard 
Medical School, P.O. Box 825, Boston, MA 02117-0825; or call 
(617) 384-8600; or e-mail ceprograms@hms.harvard.edu; or see 
http://updateinternalmedicine.com, http://nephrologyboston.com, 
or http://cmeregistration.hms.harvard.edu/MSK2020, respectively.
ADVANCED EUROPEAN BIOETHICS COURSE
The course, entitled “Suffering, Death and Palliative Care,” 
will be offered in Nijmegen, the Netherlands, March 24–27. It 
is presented by the section of Healthcare Ethics, IQ healthcare, 
Radboud University Medical Centre.
Contact Valesca Hulsman, Radboud University Medical 
 Centre, P.O. Box 9101, 114, 6500 HB Nijmegen, the Nether-
lands; or call +31 (0)24 3615305; or e-mail valesca.hulsman@
radboudumc.nl; or see https://bit.ly/2eqVZ4A.
THOMAS L. PETTY ASPEN LUNG CONFERENCE
The 63rd Annual Meeting, entitled “ARDS in the 21st Cen-
tury: New Insights into Clinical and Mechanistic Heterogene-
ity,” will be held in Aspen, CO, June 10–13. Deadline for sub-
mission of abstracts is Feb. 14.
Contact Dr. Eric Schmidt, c/o Jeanne Cleary, Thomas L. Petty 
Aspen Lung Conference, P.O. Box 1622, Parker, CO 80134; or 
call (303) 358-2797; or e-mail Jeanne.Cleary@ucdenver.edu; or 
see http://www.aspenlungconference.org.
ROOSEVELT ISLAND HISTORICAL SOCIETY
The Roosevelt Island Historical Society is seeking physi-
cians who worked on the New York City island as students, 
interns, and residents to learn about their experiences. The is-
land was known as Welfare Island until 1973.
Contact Judith Berdy, Roosevelt Island Historical Society, 
531 Main St., Roosevelt Island, NY 10044; or call (212) 688-
4836; or e-mail rooseveltislandhistory@usa.com.
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